CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

This study tests a new type of cell therapy — called bispecific CAR-T cells — that targets two proteins (CD19 and CD22) on cancer cells in people with relapsed or treatment-resistant B-cell lymphoma or B-cell leukemia. This is an immune cell therapy where the patient's own immune cells are genetically modified to attack cancer. **You may be eligible if...** - You are between 14 and 85 years old - You have B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or stopped responding to standard treatment - Your cancer tests positive for CD19 and/or CD22 proteins - You have reasonable overall health (ECOG 0-2) - Your blood counts and organ function meet required minimums **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have an uncontrolled infection, HIV, syphilis, or active hepatitis B or C - You are currently using steroids or immune-suppressing drugs - You have had previous gene therapy - You have severe heart, liver, or kidney disease - You have participated in another clinical trial in the past 3 months Talk to your doctor to see if this trial is right for you.